OrPro Therapeutics is a preclinical stage Johnson & Johnson JLABS alumni company addressing large unmet medical needs in respiratory, ophthalmology and oncology with a novel cell-protective biologic drug platform.
Meet OrPro Therapeutics
Why is your company the best option to solve the problem you're solving?
Secreted human proteins have proven to be some of the most successful blockbuster therapeutics because of their unusually high safety and efficacy in addressing large unmet medical needs. Our broad platform-in-a-product strategy, advanced manufacturing and formulation, and strong intellectual property create opportunities for early exits and multiple shots on goal vs. proven disease targets.
What else do you want us to know?
We were recently awarded a $2.147M grant from the prestigious Congressionally Directed Medical Research Programs administered by the US Department of Defense. This will fund key development milestones for our lead candidate ORP100S as a treatment for acute viral lung injury, including in vitro and in vivo evaluation in models of COVID and severe influenza. We are partnered with Mount Sinai to test our drug in their 3-D human lung organoid system and are also working on an oncology program in collaboration with Duke University.
BEHIND THE COMPANY
CEO/Founder: Peter Heifetz
What inspired you to start/run this company?
My first industry mentor, who went on to start several successful biotech companies.
What's the best entrepreneurial advice you've received?
"Hope is not a plan"